THIS WEBSITE USES COOKIES
We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.

| Host Institution | PhD enrolment | Duration |
| University of Pisa – UNIPI (Pisa, Italy) | University of Pisa – UNIPI (Pisa, Italy) | 36 months |
Main Supervisors: Prof. S. Capaccioli (UNIPI), Prof. M. Geppi (UNIPI)
Context: Enhancing the solubility of poorly water-soluble active pharmaceutical ingredients (APIs) remains one of the central challenges in modern drug development. Co-crystallisation and co-amorphisation have emerged as two promising solid-state strategies, each offering unique advantages for solubility and stability enhancement. However, the underlying duality and interconversion between these forms is still poorly understood, even though their local molecular organization and dynamics, which can often exhibit remarkable similarities.
Objectives: This doctoral project aims to unravel the fundamental structure–dynamics–dissolution relationships underlying co-crystallised and co-amorphous pharmaceutical systems. By integrating advanced solid-state characterisation and spectroscopy techniques, the project will establish a unified mechanistic frame-work explaining how structural organisation and molecular mobility influence dissolution enhancement. The ultimate goal is to enable the rational design of hybrid solid forms (e.g., semi-ordered amorphous/co-crystals) with tuneable solubility and physical stability.
Expected results: Establish clear structure–dynamics–dissolution relationships that can inform the rational design of solid pharmaceutical forms; Identification of potential hybrid intermediate states combining advantageous features of both co-crystals and co-amorphous systems may offer a novel route to achieving enhanced solubility and kinetic stability; Development of predictive models and design principles that support the formulation of more effective and sustainable drug development strategies.
Research Methodology: The doctoral candidate will employ state-of-the-art solid-state and spectroscopic techniques, making large use of high-resolution solid-state NMR, nuclear spin relaxometry, and dielectric relaxation spectroscopy, but also including PXRD, electron diffraction, DSC, FTIR, Raman spectroscopy to probe molecular structure and mobility. Dissolution studies in biorelevant media will be combined with kinetic modelling to quantify performance relationships. Mechanically (ball-milling) and thermally induced transitions will be examined to map transformation pathways between co-crystalline, co-amorphous, and hybrid states.
Planned secondments:
Comparison of solubility/dissolution performance between developed co-crystalline/coamorphous forms. Study of alternative manufacturing routes.
Exposure of the DC to industry R&D. Study of molecular interactions in developed systems.
Requirements – Skills/Qualifications: Applicants must hold a Master’s degree or equivalent in Physics, Chemistry, Materials Science or similar providing access to PhD programs and should have preferably experience with experimental research.

| Host Institution | PhD enrolment | Duration |
| Polytechnic University of Catalonia – UPC (Barcelona, Spain) | Polytechnic University of Catalonia – UPC (Barcelona, Spain) | 36 months |
Main Supervisors: Prof. M. Romanini (UPC) and Prof. C. Cazorla (UPC)
Context: Understanding and exploiting eutectic and amorphous phase behaviour offers a powerful route to enhance the dissolution and stability of poorly soluble active pharmaceutical ingredients (APIs). Eutectic systems, comprising small-molecule API–API or API–coformer combinations, exhibit characteristic melting point depressions and complex solid–liquid equilibria that can facilitate low-temperature amorphization and improve processability. Despite their potential, the thermodynamic and kinetic principles governing the formation, stability, and dissolution of such systems remain incompletely understood.
Objectives: This project aims to explore both the equilibrium and non-equilibrium phase behaviour of small-molecule binary mixtures comprising API and coformer or API–API combinations, and to elucidate their fundamental physicochemical properties. Particular emphasis will be placed on understanding eutectic phase formation and the potential of such systems to yield amorphous mixtures with improved kinetic stability and dissolution performance. Graph-based machine learning (ML) models will be employed to predict binary choices of APIs or API-excipient capable of forming eutectic mixtures with the desired compositions and melting points.
Expected results: New experimentally verified eutectic systems; Mechanistic and practical framework for using eutectics as a route to stable, high-performance amorphous drug formulations; State-of-the-art, trained convolutional graph neural networks as a predictive tool for eutectic formulation design.
Research Methodology: the doctoral candidate will integrate various methodologies:
Work location: The project will be carried out at the EEBE-CDB campus of the Universitat Politècnica de Catalunya (UPC-BarcelonaTech) located in Barcelona, Spain, with two three-months secondment periods, respectively at:
Complementary study the impact of pressure in phase diagram.
Exposure of the DC to industry R&D. Study of molecular interactions in developed systems.
Requirements – Skills/Qualifications: Applicants must hold a Master’s degree or equivalent in Physics, Chemistry, Materials science or similar providing access to PhD programs and should have preferably experience with computational methods and research.
Information about this position is also available on EURAXESS

Host Institution | PhD enrolment | Duration |
University of Silesia in Katowice – USK (Katowice, Poland) | 48 months |
Main Supervisor: Prof. M. Paluch (USK)
Context: Industrial pharmaceutical processes such as tableting, encapsulation, hot-melt extrusion, and high-pressure homogenization frequently subject materials to elevated pressures and mechanical stresses that can profoundly influence their physical state. While such stresses may trigger crystallization or enhance amorphous stability, the mechanisms governing these competing effects remain poorly understood.
Objectives: This project aims to elucidate the impact of elevated pressure on the structural, dynamical, and thermodynamic properties of co-amorphous pharmaceutical systems. Understanding the effects of pressure is of critical importance, as numerous industrial pharmaceutical processes such as tableting, encapsulation, hot-melt extrusion, and high-pressure homogenization expose materials to mechanical stresses. These stresses can either trigger crystallisation or enhance amorphous stability, yet the role of pressure in modulating amorphous–crystalline transitions remain insufficiently understood. By integrating advanced high-pressure experimental techniques with data-driven algorithms, this project seeks to unravel the mechanisms through which pressure influences the stability and phase transformations of co-amorphous systems.
Expected results: Fundamental understanding of how elevated pressure influences the stability of co-amorphous pharmaceuticals, identify pressure-stabilized amorphous states and define conditions that minimise crystallisation during processing; Pressure–temperature stability maps and predictive algorithms to enable rational formulation design, Enhancement on the development of pressure-resilient, long-lasting amorphous drug systems.
Research Methodology: The doctoral candidate will employ high-pressure spectroscopic and calorimetric techniques, including dielectric relaxation spectroscopy (DRS), differential scanning calorimetry (DSC), and infrared and Raman spectroscopy under variable-pressure conditions, to monitor structural and dynamic changes in co-amorphous systems. These measurements will elucidate the effects of compression on molecular mobility, glass transition temperature, and crystallization kinetics
Planned secondments:
Complementary studies on phase diagram.
Exposure of the DC to industry R&D. Study of aqueous solubility and dissolution profiles of investigated co-amorphous systems.
Requirements – Skills/Qualifications: Applicants must hold a Master’s degree or equivalent in Physics, Chemistry, Materials science or similar providing access to PhD programs and should have preferably experience with experimental research, spectroscopy methods and laboratory work.
Information about this position is also available on EURAXESS

| Host Institution | PhD enrolment | Duration |
| Université Catholique de Louvain – UCLouvain (Belgium) | Université Catholique de Louvain – UCLouvain (Belgium) | 48 Months |
Main Supervisor: Prof. T. Leyssens
Context: Co-amorphous systems, formed by combining an active pharmaceutical ingredient (API) with a low-molecular-weight coformer into a single homogeneous amorphous phase, represent a promising strategy to enhance the solubility and stability of poorly water-soluble drugs. However, the physical properties and performance of co-amorphous materials are highly dependent on the manufacturing route and processing history, which can significantly influence molecular organization, relaxation dynamics, and recrystallization resistance.
Objectives: This doctoral project aims to advance the new field of “co-amorphous engineering” investigating how various manufacturing techniques, including spray-drying, freeze-drying, hot-melt extrusion, high-energy milling, and melt-quenching, impact the structure, molecular dynamics, physical stability, solubility, and dissolution behaviour of low-molecular-weight co-amorphous systems. Through an integrated experimental strategy, the project will establish robust process–structure–property relationships to guide the rational design of physically stable, high-performance co-amorphous formulations.
Expected results: Quantitative understanding of how different synthetic routes affect the structure, dynamics, and stability of low-molecular-weight co-amorphous systems; Establish predictive process–property maps and data-driven guidelines for co-amorphous engineering, enabling formulators to design systems with enhanced stability, solubility, and dissolution rates; Rational basis for the selection of coformers and processing conditions, paving the way for scalable, reproducible, and sustainable manufacturing of amorphous formulations.
Research Methodology: The doctoral candidate will prepare model co-amorphous systems using complementary bottom-up and top-down manufacturing techniques, varying process parameters such as temperature, solvent, and cooling rate to explore the influence of processing history. Structural and dynamic properties will be characterized using DSC, PXRD, FTIR, Raman spectroscopy, dielectric relaxation spectroscopy, and solid-state NMR, while dissolution studies in biorelevant media will provide performance correlations.
Planned secondments:
Study of how the synthetic approach impacts the molecular mobility and intermolecular interactions in co-amorphous systems developed.
Exposure of the DC to industry R&D. Study of stability, dissolution and solubility of co-amorphous systems.
Requirements – Skills/Qualifications: Applicants must hold a Master’s degree or equivalent in Physics, Engineering, Chemistry, Materials science or similar providing access to PhD programs and should have preferably experience with experimental research.

Host Institution | PhD enrolment | Duration |
University of Lille – ULille (France) | 36 months |
Main Supervisors: Dr. F. Ngono Mebenga (Janssen Pharmaceutica), Prof. N. Correia (ULille), Prof. F. Affouard (ULille)
Context: The rational design of stable and high-performing pharmaceutical solid forms—such as co-crystals and co-amorphous systems—requires a detailed understanding of the molecular interactions that control their nucleation, structure, and stability. These systems are governed by complex, cooperative networks of noncovalent interactions—including hydrogen bonding, π–π stacking, halogen and chalcogen bonding, and ion–dipole interactions—which collectively define their thermodynamic and kinetic behaviour.
Objectives: The main objective of this project is to achieve a precise molecular-level characterisation of the intermolecular interactions governing the formation and stability of pharmaceutical co-crystals and co-amorphous systems. This project will deliver a precise, molecular-scale understanding of how specific intermolecular interactions (hydrogen bonding, π–π stacking) drive nucleation (in solvent environment), structure, stability and improved biorelevant dissolution in both pharmaceutical co-crystals and co-amorphous systems. By integrating advanced spectroscopy, diffraction, calorimetry, solid-state NMR, and molecular modelling (MD simulation, DFT computation) with targeted case studies, we will build quantitative structure–interaction–property relationships.
Expected results: Validated transferable methodology for rational design and prediction of stable co-crystal and co-amorphous systems accelerating the development of optimised pharmaceutical solid forms with enhanced bioavailability and manufacturability; Industrial translation of the developments obtained in WP1.
Research Methodology: The doctoral candidate will employ a synergistic experimental–computational strategy combining:
Experimental and theoretical data will be integrated into quantitative structure–interaction–property relationships (QSIPRs) to rationalize stability and dissolution behaviour across molecular systems.
Planned secondment:
In-silico and dielectric relaxation experiments on the developed amorphous formulations
Requirements – Skills/Qualifications: Applicants must hold a Master’s degree or equivalent in Physics, Chemistry, Materials Science or similar providing access to PhD programs and should have preferably experience with experimental and computational research

Host Institution | PhD enrolment | Duration |
University of Lille – ULille (France) | 36 months |
Main Supervisors: Prof. F. Affouard (ULille), Prof. E. Dudognon (ULille)
Context: Amorphous solid dispersions (ASDs), where an active pharmaceutical ingredient (API) is molecularly dispersed within a polymeric matrix, are a leading strategy to overcome poor aqueous solubility and enhance bioavailability. Despite their promise, the molecular mechanisms that control API–polymer miscibility, amorphization, and long-term stability remain insufficiently understood, limiting rational formulation design.
Objectives: This project aims to provide fundamental molecular-level insights into API–polymer interactions that dictate the formation and stabilization of ASDs. By integrating multi-scale computational modelling, data-driven machine learning approaches, and complementary experimental validations, the DC will develop a predictive framework linking molecular structure to macroscopic performance of amorphous formulations thereby enabling the rational design of next-generation ASD formulations.
Expected results: A molecular-level understanding of drug-drug, drug–polymer and polymer–polymer interactions governing amorphous stabilization; predictive models linking polymer architecture, topology, and chirality to API miscibility and physical stability; Quantitative insights guiding the rational design of next-generation ASD systems; Experimentally validated computational tools and protocols transferable to industrial formulation screening.
Research Methodology: The doctoral candidate will integrate various methodologies:
Planned secondments:
Validation of computational predictions with respect to chirality.
Exposure of the DC to industry R&D. Study of stability, dissolution and solubility properties of ASDs developed using various techniques.
Requirements – Skills/Qualifications: Applicants must hold a Master’s degree or equivalent in Physics, Materials science or similar providing access to PhD programs and should have preferably experience with computational research.

Host Institution | PhD enrolment | Duration |
University of Silesia in Katowice – USK (Katowice, Poland) | 48 months |
Main Supervisors: Prof. K. Kamiński (USK) and Prof. M. Tarnacka (USK)
Context: Polymeric excipients are key components in amorphous solid dispersions (ASDs), where they stabilize amorphous drug forms and modulate release kinetics. However, the molecular design principles that link polymer microstructure and topology to ASD performance remain poorly understood. This project aims to design, synthesize, and characterize next-generation biocompatible polymers and copolymers with precisely controlled chain architecture, topology, and amphiphilicity to achieve tunable stabilization and dissolution of active pharmaceutical ingredients (APIs).
Objectives: This project aims to design, synthesise, and characterise next-generation biocompatible polymers and copolymers with precisely tailored microstructure, chain topology, and amphiphilicity to achieve controlled stabilization and dissolution of selected APIs. By integrating advanced polymer synthesis, comprehensive physicochemical characterisation, and collaborative computational modelling, the project will uncover the structure–property relationships that govern polymer-mediated stabilization and release in ASDs.
Expected results: Identification of polymer architectures and topologies that maximize API stabilization and enable tuneable release kinetics; Mechanistic understanding of how polymer microstructure and topology govern amorphous stability and dissolution control; Development of structure–property–function relationships guiding the rational design of polymeric excipients for diverse APIs; Generation of polymer libraries and design principles transferable to industrial formulation development.
Research Methodology: The doctoral candidate will synthesize biocompatible polymers and copolymers (e.g., PEG, PCL, PLA derivatives) using controlled polymerization techniques such as RAFT, ATRP, and ROP, enabling precise control of chain length, branching, and amphiphilicity. Polymer architecture will be systematically varied (linear, block, graft, cyclic) to probe how microstructural features influence drug–polymer interactions and amorphous stability. Comprehensive characterization will be conducted using NMR, GPC, DSC, PXRD, FTIR, and SAXS to assess chemical composition, molecular weight distribution, morphology, and thermal transitions.
Planned secondments:
Study of the interactions between polymers and APIs.
Exposure of the DC to industry R&D. Study of dissolution and solubility properties of the various formulations consisted of biocompatible polymers and copolymers with varying microstructure and topology.
Requirements – Skills/Qualifications: Applicants must hold a Master’s degree or equivalent in Physics, Chemistry, Materials science or similar providing access to PhD programs and should have preferably experience with experimental research, spectroscopy methods and laboratory work.
Information about this position is also available on EURAXESS

Host Institution | PhD enrolment | Duration |
Université Catholique de Louvain – UCLouvain (Belgium) | 48 Months |
Main Supervisor: Prof. T. Leyssens
Context: Chirality is a fundamental molecular property that significantly affects molecular recognition and interaction patterns in pharmaceutical systems. Although most active pharmaceutical ingredients (APIs) are chiral, the influence of excipient chirality on miscibility, stability, and release behaviour in amorphous solid dispersions (ASDs) remains largely unexplored.
Objectives: This project aims to provide a molecular-level understanding of how excipient chirality governs the physical stability and performance of ASDs, establishing new design principles for chiral excipient selection and formulation.
Expected results: Molecular-level understanding of how excipient chirality influences molecular packing, relaxation dynamics, and structural organisation within amorphous solid dispersions; Identification of chiral API–polymer combinations that provide enhanced amorphous stability, improved shelf-life, or tailored drug release profiles; Establishment of structure–property relationships linking excipient chirality to API miscibility, glass transition temperature, and dissolution behaviour; Development of design principles for the rational selection and synthesis of chiral excipients and stabilisers in ASD formulations.
Research Methodology: The doctoral candidate will prepare ASDs using enantiopure polymers and excipients, such as D- and L-polylactic acid, enantiopure PVP, poly-L-histidine, sucrose, and ribose. Structural and dynamical properties will be characterized using DSC, PXRD, FTIR, Raman spectroscopy, dielectric relaxation spectroscopy, and solid-state NMR. The impact of chirality on molecular packing, glass transition, and relaxation dynamics will be quantified, and dissolution performance will be assessed in biorelevant media.
Planned secondments:
Advanced synthesis to obtain block polymers with specific chiral domains to get to controlled release.
Exposure of the DC to industry R&D. Scale-up and accelerated stability testing of chiral ASDs.
Requirements – Skills/Qualifications: Applicants must hold a Master’s degree or equivalent in Chemistry, Materials science or similar providing access to PhD programs and should have preferably experience with experimental research.

Host Institution | PhD enrolment | Duration |
Trinity College Dublin – TCD (Dublin, Ireland) | 36 months |
Main Supervisor: Prof. L. Tajber (TCD)
Context: High-melting and poorly processable active pharmaceutical ingredients (APIs) present persistent challenges in the formulation of amorphous solid dispersions (ASDs), often requiring harsh thermal or solvent-based processes that compromise stability, scalability, and environmental sustainability. Eutectic systems—comprising combinations of safe, biocompatible hydrogen bond donors and acceptors—offer a novel route to reduce effective melting points, enhance solvation, and enable low-temperature processing.
Objectives: This project aims to develop hybrid eutectic–polymer systems as next-generation ASD matrices that combine the plasticization capacity of eutectics with the stabilising and mechanical properties of polymers. The research will establish fundamental design principles and mechanistic understanding of how eutectic–polymer interactions modulate amorphization, stability, and drug release in challenging APIs.
Expected results: Identification of hybrid eutectic–polymer systems capable of effectively amorphising high-melting or poorly soluble APIs; Mechanistic understanding of how eutectic–polymer interactions influence solubility, miscibility, molecular mobility, and long-term physical stability; Development of formulation design guidelines for using eutectic-based hybrids as next-generation ASD matrices with tuneable properties; Contribution to sustainable pharmaceutical innovation through the application of green, biocompatible solvents and polymers.
Research Methodology: Hybrid eutectic–polymer ASDs will be prepared using spray drying, solvent evaporation, and melt-quenching methods, employing model solvents combined with biocompatible polymers such as PVP, HPMC, and Eudragit®. Thermal and structural properties will be investigated using DSC, TGA, PXRD, FTIR, and solid-state NMR, while miscibility, glass transition behaviour, and relaxation dynamics will be systematically assessed.
Planned secondments:
Characterization of molecular mobility of most promising eutectic-polymer hybrid systems for long-term stability control.
Industrial experience and scale up of successful ASDs.
Requirements – Skills/Qualifications: Applicants must hold a BSc degree (at least 2.1 honors degree level or an equivalent result) in Pharmacy, Pharmaceutical Sciences, Materials Science, Chemistry or a related subject. A Master’s degree is desirable, and applicants should preferably have experience in experimental research. Proficiency in written and spoken English (IELTS 6.5 or equivalent, full list of qualifications can be found here; proof required)
Information about this position is also available on EURAXESS

Host Institution | PhD enrolment | Duration |
Trinity College Dublin – TCD (Dublin, Ireland) | 36 months |
Main Supervisors: Dr. P. Stasiak (Zentiva), Prof. L. Tajber (TCD)
Context: The industrial deployment of next-generation amorphous solid dispersions (ASDs) requires effective translation of laboratory-scale innovations into robust, scalable, and reproducible manufacturing processes. Hot-melt extrusion (HME) and related continuous processing technologies offer significant potential for this purpose, but process optimization is challenging for complex formulations such as chiral systems, hybrid eutectic–polymer matrices, and topology-controlled polymers.
Objectives: This project, conducted by industrial partners, aims to develop and optimise extrusion-based processing routes for next-generation ASD systems developed in the network including chiral systems, eutectic–polymer hybrids, and topology-controlled polymers. By combining process development, analytical monitoring, and modelling, the project will establish process–structure–property relationships that underpin reliable large-scale production of complex amorphous formulations. The research will thus bridge the gap between materials innovation and manufacturability, enabling the industrial deployment of emerging ASD technologies.
Expected results: Optimised extrusion protocols for new ASD systems incorporating advanced polymers, hybrid eutectic–polymer matrices and chiral excipients developed by other DCs; Quantitative understanding of processability and scalability, linking formulation chemistry to extrusion behaviour and final product performance; Predictive process–structure–property relationships supporting robust, reproducible, and cost-effective ASD manufacturing; Industrial implementation guidelines for integrating next-generation amorphous formulation technologies into full scale continuous or semicontinuous manufacturing.
Research Methodology: The doctoral candidate will optimize extrusion parameters (temperature profile, screw configuration, residence time, and feed rate) to achieve optimal amorphization and minimize thermal or mechanical degradation. Process analytical technologies (PAT)—including near-infrared (NIR) and Raman spectroscopy, torque monitoring, and temperature sensing—will be integrated for real-time monitoring of process stability and material transformation. Extrudates will be characterized using DSC, PXRD, DMA, and SEM to assess amorphous content, miscibility, morphology, and mechanical properties. Data will be used to develop empirical and mechanistic models correlating process conditions with final product quality and performance.
Planned secondments:
Advanced characterisation of processed ASDs (thermal, mechanical, and solid-state analysis).
Assessing and understanding dissolution and shelf-life stability of upscaled eutectic-based ASDs.
Requirements – Skills/Qualifications: Applicants must hold a BSc degree (at least 2.1 honors degree level or an equivalent result) in Pharmacy, Pharmaceutical Sciences, Materials Science, Chemistry or a related subject. A Master’s degree is desirable, and applicants should preferably have experience in experimental research. Proficiency in written and spoken English (IELTS 6.5 or equivalent, full list of qualifications can be found here; proof required).

Host Institution | PhD enrolment | Duration |
University of Lille – ULille (France) | 36 months |
Main Supervisors: Prof. F. Affouard (ULille), Prof. N. Correia (ULille)
Context: The formulation of complex therapeutic molecules remains a major challenge in pharmaceutical development. Compared with conventional small molecules, proteins and PROTACs (Proteolysis-Targeting Chimeras) exhibit greater structural complexity, higher conformational flexibility, and increased sensitivity to processing and storage conditions. These features often lead to poor physical stability, limited solubility, very low absorption, moisture sensitivity, and a high risk of degradation or phase transformation. Amorphous formulations are especially attractive because they can improve apparent solubility and bioavailability, but their design still relies heavily on empirical screening. This trial-and-error approach is time- and material-intensive and poorly suited to emerging drug modalities.
Objectives: The main objective of this project is to develop a predictive toolbox for the design of amorphous formulations for complex molecules, using proteins and PROTACs as representative case studies. The specific objectives are to: identify molecular descriptors governing amorphous stability, including conformational flexibility, intermolecular interactions, hydrogen-bonding capacity, and excipient miscibility; establish molecular modelling workflows capable of predicting formulation-relevant properties such as glass transition temperature (Tg), glass-forming tendency, interaction strength, molecular mobility, and phase behaviour; understand the origin of the low absorption and how can it be improved by adding certain excipients and validate model predictions through selected experimental studies.
Expected Results: The project is expected to deliver a validated predictive toolbox integrating numerical modelling and experimental data for accelerated formulation design. It will generate numerical models capable of relevant properties for formulations and establish an experimental-computational workflow that reduces empirical screening while improving efficiency.
Research Methodology:
The project will adopt a molecular modelling-driven approach complemented by focused experimental validation. It will combine computational atomistic modelling and machine learning to develop predictive models for Tg, miscibility, and amorphous stability; experimental characterization using thermal, structural, and functional analyses to validate and refine the models; and integration into a hybrid predictive toolbox for real-time formulation screening. Validation will be performed on proteins and PROTACs under industrially relevant conditions.
Planned secondments:
Experimental validations and tests of the developed numerical methods.
Exposure of the DC to industry R&D. Release testing using a novel technology developed by the host.
Requirements – Skills/Qualifications: Applicants must hold a Master’s degree or equivalent in Physics, Materials science or similar providing access to PhD programs and should have preferably experience with computational research.
Information about this position is also available on EURAXESS

Host Institution | PhD enrolment | Duration |
NOVA University of Lisbon – UNL (Lisbon, Portugal) University of Lille – ULille (France) | 36 months |
Main Supervisors: Prof. M. Dionisio (UNL), Prof. Ines Matos (UNL) and Prof. N. Correia (ULille)
Context: Controlling the release of active pharmaceutical ingredients (APIs) from nanostructured carriers represents a promising strategy to enhance drug solubility, stability, and therapeutic performance. Mesoporous silica materials (e.g., MCM-41, SBA-15) provide highly tuneable pore structures and surface chemistries that can host APIs within nanoconfined environments, allowing for precise modulation of drug–host interactions and release kinetics. However, achieving predictable and sustained release remains challenging due to factors such as molecular mobility of the confined API, particle aggregation, limited dispersion, and variable interactions with biological media.
Objectives: This project aims to develop chemically modified nanosilica–biopolymer composites capable of precisely tuning API release profiles. It will correlate API delivery behaviour with i) guest molecular dynamics governed by interactions with the nanoparticle silica surface and ii) the dispersion of API–silica complexes (API–RSi) within biocompatible polymer matrices. The project will uncover structure–dynamics–property–performance relationships that control release rate, stability, and bioavailability.
Expected results: Controlled API–RSi host interactions achieved through targeted chemical modification of mesoporous silica surfaces; Enhanced physical stability, shelf-life, and solubility of APIs through nanoconfinement and polymer integration; Tuneable drug release kinetics achieved by adjusting surface chemistry and polymer matrix diffusion properties; Development of biocompatible silica–polymer nanocomposites with improved dispersion and reduced particle aggregation.
Research Methodology: The doctoral candidate will synthesize mesoporous silica hosts (MCM-41, SBA-15) with tunable pore sizes (3–10 nm) and surface functionalities (e.g., –OH, –NH₂, –COOH, –CH₃) via chemical grafting and silanization techniques. APIs will be loaded into these modified hosts to form API–RSi complexes, and their molecular mobility will be probed by DRS, the physicochemical properties—such as loading capacity, dispersion, and interaction strength—will be analysed using BET surface analysis, FTIR, solid-state NMR, and DSC. To improve dispersion and bioavailability, the API–RSi complexes will be embedded into biocompatible polymer (e.g., PLA, PCL, chitosan) using green processing methods. The resulting nanocomposites will be characterized for morphology (SEM, TEM), thermal stability, and release behaviour in biorelevant media.
Planned secondments:
Requirements – Skills/Qualifications: Applicants must hold a Master’s degree or equivalent in Physics, Chemistry, Materials science or similar providing access to PhD programs and should have preferably experience with experimental research.
Information about this position is also available on EURAXESS

Host Institution | PhD enrolment | Duration |
Polytechnic University of Catalonia – UPC (Barcelona, Spain) | Polytechnic University of Catalonia – UPC (Barcelona, Spain) | 36 months |
Main Supervisors: Prof. R. Macovez (UPC) and Prof. M. Romanini (UPC)
Context: The efficient delivery of biopharmaceuticals—such as peptides, proteins, and nucleic acids—remains a major challenge due to their intrinsic instability, sensitivity to environmental conditions, and limited permeability across biological barriers. Nanoparticle-based drug carriers can protect labile biomolecules from degradation, while at the same time offering a large surface-to volume ratio to enable active control of drug release. However, their use in biopharmaceutical delivery requires improved control of surface chemistry, biocompatibility, and hybrid functionality to achieve both stabilization and targeted release
Objectives: This project aims to design, synthesise, and characterise two types of nanoparticle carriers, and the stability and release kinetics of loaded APIs: 1) hybrid mesoporous silica nanoparticles (MSNs), with tuneable pore size and large internal surface area of controlled chemical composition for API loading; 2) amorphous polymer microparticles (PMPs) encapsulating the API-loaded MSNs. In the first case, it is the porous silica structure alone that plays the function of encapsulating/stabilising and preventing the degradation of labile or sensitive biopharmaceuticals. In the second case, the polymer matrix provides a multistage delivery profile, where the PMPs protect the API-loaded MSNs, releasing the MSNs at the desired location, that in turn provide a controlled release of the API. These hybrid systems will exploit organic–inorganic inorganic-polymer interactions for optimal drug loading, protection, and controlled release, providing a platform for next-generation hierarchical nanoparticle-based delivery systems with enhanced efficacy and safety.
Expected results: Novel hybrid nanoparticles with optimised interfacial chemistry for efficient stabilization and delivery of biopharmaceuticals; Release control as a function of sample architecture; Mechanistic understanding of how nanoparticle composition and structure affect drug encapsulation, release, and molecular stability; Validated hybrid platform technology adaptable for diverse therapeutic molecules and delivery routes; Enhanced biocompatibility and performance, enabling safer and more effective delivery of fragile biomolecules.
Research Methodology: the doctoral candidate will integrate various methodologies:
Work location: The candidate will be enrolled his/her PhD at the EEBE-CDB campus of the Universitat Politècnica de Catalunya (UPC-BarcelonaTech), located in Barcelona, Spain, where he/she will work during 24 months in the Group of Characterization of Materials, under the supervision of prof. R. Macovez and prof. M. Romanini. These two years will include a 3-month secondment period at the company Linari Engineering, located in Pisa, Italy, to gain industrial experience on advanced electrospinning equipment for building polymeric nanostructured materials containing nanoparticles.
During the remaining 12 months, roughly at the beginning of the project and corresponding to the academic year 2027-2028, the candidate will work at the Instituto Superior Técnico (IST), Universidade de Lisboa, located in Lisbon, Portugal, under the supervision of Prof. J. P. Farinha and Prof. C. Baleizão, to work on the preparation and quality assessment of hybrid mesoporous silica nanoparticles by TEM, DLS, NMR and Raman, and of hybrid polymer microparticles with encapsulated nanoparticles by SEM
Requirements – Skills/Qualifications: Applicants must hold a Master’s degree or equivalent in Chemistry, Materials science, Physics or similar, providing access to PhD programs, and should have preferably experience
Information about this position is also available on EURAXESS

Host Institution | PhD enrolment | Duration |
University of Pisa – UNIPI (Pisa, Italy) | 36 months + about 3 months for external evaluation and defence |
Main Supervisors: Prof. S. Danti (UNIPI), Prof. G. Gallone (UNIPI)
Context: Emerging “4D biopharmaceuticals” represent the next generation of smart therapeutic systems capable of responding dynamically to external stimuli. Among these, photo-responsive polymeric materials offer unique opportunities for spatiotemporal control of drug release, molecular conformation, and therapeutic activity. Near-infrared (NIR) light is particularly attractive for biomedical use due to its deep tissue penetration and non-invasive activation potential.
Objectives: This project aims to develop polymer-based materials and hybrid structures ranging from nanoscale carriers to macroscale scaffolds with electromagnetically activated functionalities responsive to NIR irradiation. These materials will enable controlled, on-demand drug release and adaptive therapeutic performance, establishing the foundation for 4D biopharmaceutical platforms that integrate material responsiveness, biocompatibility, and precision functionality.
Expected results: Novel polymer-based photo-responsive materials exhibiting controlled and reversible activation under NIR light; Multi-scale structures (nano to macro) enabling spatiotemporally controlled drug release or therapeutic activation; Fundamental understanding of electromagnetic activation mechanisms in polymeric matrices and their relationship to molecular mobility and release kinetics; Demonstration of 4D biopharmaceutical platforms combining stimuli-responsiveness, biocompatibility, and functional adaptability.
Research Methodology: The doctoral candidate will design photo-responsive polymer networks incorporating NIR-absorbing chromophores or plasmonic nanomaterials (e.g., gold or carbon/ceramic-based nanoparticles) as activation components. Synthesis will involve controlled polymerization and functionalization techniques (e.g., RAFT, ATRP, click chemistry) to introduce light-sensitive moieties and crosslinkable segments. The materials will be processed into multiscale structures—such as nanoparticles, hydrogels, and porous scaffolds—using 3D printing, electrospinning, and emulsion templating. Structural and functional characterization will include UV–Vis–NIR spectroscopy, FTIR, DSC, TGA, SEM/TEM, rheology, and dynamic light scattering (DLS). Drug loading and light-triggered release will be evaluated under simulated physiological conditions using photo-irradiation setups, while biocompatibility assays will assess the materials’ suitability for biomedical use.
Planned secondments:
Requirements – Skills/Qualifications: Applicants must hold a Master’s degree or equivalent in Physics, Chemistry, Materials Science, Chemical Engineering, Biomedical Engineering or similar providing access to PhD programs and should have preferably experience with experimental research.
Information about this position is also available on EURAXESS

Host Institution | PhD enrolment | Duration |
University of Pisa (Italy) | 36 months |
Main Supervisors: Dr. N. Günday-Türeli (MyBiotech) and Prof. S. Danti (UNIPI)
Context: Biopharmaceuticals—such as proteins, peptides, and biologics—are revolutionizing modern medicine but remain challenging to formulate and deliver due to their structural fragility, instability, and susceptibility to degradation. Polymeric nanoparticle-based delivery systems offer a promising strategy to enhance stability, control release kinetics, and improve bioavailability. However, their production through conventional batch methods often suffers from poor reproducibility, limited scalability, and significant solvent and energy consumption.
Objectives: This project aims to develop protein-loaded polymeric nanoparticles using green and continuous microfluidic reactor technologies. These systems will enable precise control over particle size, morphology, and release behaviour while minimizing solvent waste and energy usage. The resulting delivery platforms will provide tuneable, stable, and sustainable carriers for a wide range of therapeutic biomolecules.
Expected results: Protein-loaded polymeric nanoparticles with tuneable size, morphology, and release kinetics, produced by green continuous microfluidic technology; Establishment of process–structure–property relationships for predictive design of nanoparticle-based biopharmaceutical formulations; Environmentally sustainable and scalable manufacturing protocols, reducing solvent use, waste generation, and energy consumption; Improved encapsulation efficiency and stability of therapeutic proteins and peptides, enhancing bioavailability and therapeutic efficacy. Industrial translation of the developments obtained.
Research Methodology: The doctoral candidate will employ microfluidic reactor systems as eco-efficient, continuous manufacturing tools for the production of protein-loaded polymeric nanoparticles. Microreactor platforms provide precise control over mixing, residence time, and solvent exchange, leading to nanoparticles with narrow size distribution and high reproducibility. Key materials will include biocompatible and biodegradable polymers such as PLGA, PEG, and chitosan derivatives. Process conditions will be optimized for high encapsulation efficiency and protein stability. The influence of microreactor design and operational parameters (channel geometry, flow ratio, solvent polarity) on particle size and drug release will be systematically studied. Tangential Flow Filtration (TFF) may be integrated as a downstream purification step to remove non-incorporated materials and concentrate the formulation. Comprehensive characterization will be performed using DLS, TEM, DSC, FTIR, and UV–Vis spectroscopy, along with in vitro release and stability assays under physiologically relevant conditions.
Planned secondments:
Prof. S. Danti (University of Pisa, Italy). Advanced physicochemical characterisation.
Requirements – Skills/Qualifications: Degree in life science (chemistry, pharmacy, biotechnology, etc) or related field. MSc or equivalent is a must. Experience in at least one of the following areas: chemistry, (bio)chemical engineering, pharmacy, pharmaceutical technology, biotechnology. Practical experience in laboratory environment is a plus. Basic knowledge of data analysis and Microsoft Office. Good organisation and communication skills, willing to travel for short or longer periods. Flexible and co-operative with a well-structured and autonomous working style. Fluency in written and spoken English is a must. German knowledge is a plus.
Information about this position is also available on EURAXESS
To apply, please send an email to coordinator-ideas@univ-lille.fr with all the required documents. Please title the email: “IDEAS application[your first and last name]”.
Required application materials:
Please submit all documents in the PDF format with the following naming convention:
[YOUR LAST NAME, YOUR FIRST NAME]_Application form.pdf
[YOUR LAST NAME, YOUR FIRST NAME]_Attachment 1 – Research Expose.pdf
[YOUR LAST NAME, YOUR FIRST NAME]_Attachment 2 – CV.pdf
[YOUR LAST NAME, YOUR FIRST NAME]_Attachment 3 – Academic record.pdf
[YOUR LAST NAME, YOUR FIRST NAME]_Attachment 4 – ID and mobility.pdf
[YOUR LAST NAME, YOUR FIRST NAME]_Attachment 5 – English.pdf (if available)
You only need to submit one application, in which you can select up to three projects.
You may also select projects that are not yet open for applications. Your application will be considered once these positions become available.
Please note that you may also be contacted regarding projects for which you have not specifically applied, particularly if no suitable candidates are found for those positions.
Only complete applications sent on time will be considered for the selection procedure. The shortlisted candidates at some of the partner institutions might then need to apply also through the institution’s official recruitment channels.